High expression of ACE2 in HER2 subtype of breast cancer is a marker of poor prognosis.
Cancer Treat Res Commun
; 27: 100321, 2021.
Article
in English
| MEDLINE | ID: covidwho-1385378
ABSTRACT
BACKGROUND:
ACE2 a key molecule of the Renin-Angiotensin system has been identified as the receptor for SARS-CoV-2 entry into human cells. In the context of human cancers, there is evidence that ACE2 might function as a tumor suppressor. The expression levels of ACE2 among the different subtypes of breast cancer has not been investigated.METHODS:
We have examined the differential expression of ACE2 and its correlation with prognosis in breast cancer subtypes using the METABRIC (n = 1898) and TCGA (n = 832) cohorts. Correlations were evaluated by Pearsons's correlation co-efficient and Kaplan-Meier analysis was used to estimate differences in disease-free survival between the ACE2 high and ACE2 low groups.RESULTS:
There is minimal expression of ACE2 in the luminal classes, but significantly higher levels in the Basal-like and HER2-enriched subclasses. Metastatic biopsies of these tumor types also show enhanced expression of ACE2. High levels of ACE2 correlated with decreased disease-free survival in the HER2-enriched subtype, and it was positively correlated with EGFR expression.CONCLUSION:
These observations suggest ACE2 might function as a context dependent factor driving tumor progression in breast cancer and permit new opportunities for targeted therapy.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Biomarkers, Tumor
/
Receptor, ErbB-2
/
Angiotensin-Converting Enzyme 2
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Limits:
Female
/
Humans
/
Middle aged
Language:
English
Journal:
Cancer Treat Res Commun
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS